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INTRODUCTION
Klebsiella pneumoniae is a very important cause of morbidity
and mortality in Gram-negative bacteremia (1). It is a com-
mon nosocomial pathogen, causing urinary tract infections,
pneumonia, and intraabdominal infections (1-4). In a past
decade, the emergence of extended-spectrum beta-lactamases
(ESBL) in K. pneumoniae strains and their dissemination have
greatly complicated chemotherapy, and outbreak due to ES-
BL-producing organisms have been reported in several coun-
tries (5-7). Ciprofloxacin (CIP) resistance rate in K. pneumo-
niae strains is also increasing in recent years (7-9). 
K. pneumoniae is also a potential community-acquired pa-
thogen. A previous international collaborative study evaluat-
ed geographic differences and trends in the prominent presen-
tations of community-acquired Klebsiella infection (10). A
striking clinical finding concerning a new manifestation of
community-acquired K. pneumoniae infections has been doc-
umented (10). An unusual invasive presentation of K. pneu-
moniae infection, primary bacteremic liver abscess, has been
described by numerous investigators in Asia (1, 10, 11). How-
ever, little data were available on the clinical and microbiologi-
cal characteristics of nosocomial vs. community-acquired K.
pneumoniae bacteremia in the era of a high rate of antimicrobial
resistance. 
In the present study, we thus describe a recent five-year sur-
vey of K. pneumoniae bacteremia, with a high rate of antimicro-
bial resistance, and the clinical-epidemiological features of
377 patients. We conducted this study to compare the clini-
cal features, treatment outcomes, and clinical implication of
antimicrobial resistance in K. pneumoniae bacteremia acquired
as community versus nosocomial infection.
MATERIALS AND METHODS
Patients and bacterial strains
The database at our Clinical Microbiology Laboratory (Seoul
National University Hospital, Seoul, Korea) was reviewed
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Community-Acquired versus Nosocomial Klebsiella pneumoniae
Bacteremia: Clinical Features, Treatment Outcomes, and Clinical 
Implication of Antimicrobial Resistance
We conducted this study to compare clinical features, outcomes, and clinical impli-
cation of antimicrobial resistance in Klebsiella pneumoniae bacteremia acquired as
community vs. nosocomial infection. A total of 377 patients with K. pneumoniae bac-
teremia (191 community-acquired and 186 nosocomial) were retrospectively ana-
lyzed. Neoplastic diseases (hematologic malignancy and solid tumor, 56%) were
the most commonly associated conditions in patients with nosocomial bacteremia,
whereas chronic liver disease (35%) and diabetes mellitus (20%) were the most
commonly associated conditions in patients with community-acquired bacteremia.
Bacteremic liver abscess occurred almost exclusively in patients with community-
acquired infection. The overall 30-day mortality was 24% (91/377), and the mortali-
ty of nosocomial bacteremia was significantly higher than that of community-acquired
bacteremia (32% vs. 16%, p<0.001). Of all community-acquired and nosocomial
isolates, 4% and 33%, respectively, were extended-spectrum cephalosporin (ESC)-
resistant, and 4% and 21%, respectively, were ciprofloxacin (CIP)-resistant. In noso-
comial infections, prior uses of ESC and CIP were found to be independent risk fac-
tors for ESC and CIP resistance, respectively. Significant differences were identified
between community-acquired and nosocomial K. pneumoniae bacteremia, and the
mortality of nosocomial infections was more than twice than that of community-ac-
quired infections. Antimicrobial resistance was a widespread nosocomial problem
and also identified in community-acquired infections.
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in order to identify patients with K. pneumoniae bacteremia.
Patients older than 16 yr of age with K. pneumoniae bacteremia
were included in the analysis. Only the first bacteremic epi-
sode for each patient was included in the analysis. We reviewed
the medical records of individuals diagnosed from January
1998 to December 2002 at Seoul National University Hos-
pital, Seoul, Korea, a 1,500-bed tertiary care university hos-
pital and referral center.
Species identification was carried out with Vitek-GNI Card
(bioMerieux, Hazelwood, MO, U.S.A.) by standard methods,
and antibiotic susceptibility testing was performed using the
disk diffusion method, following the recommendations of
the National Committee for Clinical Laboratory Standards
(12). Strains showing inhibition zone diameters in the inter-
mediate range were considered resistant.
Study design and data collection
A retrospective observational cohort study was conducted
to evaluate clinical features, treatment outcomes, and clinical
implication of antimicrobial resistance in K. pneumoniae bac-
teremia. We compared data from patients with community-
acquired K. pneumoniae bacteremia with data from those with
nosocomial bacteremia. 
We reviewed the medical records of the patients. The data
collected included age, gender, underlying diseases, primary
sites of infection, severity of illness as calculated by the Acute
Physiology and Chronic Health Evaluation (APACHE) II
score (13), and the antimicrobial therapy regimen. The pres-
ence of the following comorbid conditions was also documen-
ted: neutropenia, presentation with septic shock, care in inten-
sive care unit (ICU), receipt of immunosuppressive agents
within 30 days prior to onset of the bacteremia, corticosteroid
use, the presence of a central venous catheter or of an indwel-
ling urinary catheter, and post-operative state. The main out-
come measure used was the 30-day mortality rate. 
Definitions
K. pneumoniae bacteremia was defined as the isolation of K.
pneumoniae in a blood culture specimen. Onset of bacteremia
was defined as the date when the first positive blood culture
was obtained. Extended-spectrum cephalosporins (ESC) resis-
tance was defined as resistance in vitro to cefotaxime or cef-
tazidime. The antimicrobial therapies were classified into
empirical and definitive, the former being defined as the ini-
tial therapy before the results of blood culture were available,
and the latter as therapy after the result of antibiotic suscep-
tibility tests had been received. The antimicrobial therapy
was considered ‘appropriate’ if the treatment regimen includ-
ed at least one antimicrobial agent active in vitro against K.
pneumoniae, and if the dosage and route of administration con-
formed to current medical standards. We considered antimi-
crobial therapy to be ‘inappropriate’ if the drugs used did not
have in vitro activity against the isolated strain or if the pa-
tient did not receive antimicrobial therapy. The bacteremia
was categorized as polymicrobial if additional microorganisms
were recovered from the blood cultures. Nosocomial infec-
tion was defined as an infection that occurred ≥48 hr after
hospital admission; an infection that occurred <48 hr after
admission to the hospital, in patients that had been hospital-
ized in the 2 weeks prior to admission; and an infection that
occurred <48 hr after admission to the hospital in patients
that had been transferred from another hospital or nursing
home. The primary site of infection was determined using
clinical criteria and isolation of the bacteremic organism from
sources other than blood (14). Neutropenia was defined as an
absolute neutrophil count below 500/ L. Septic shock was
defined as sepsis associated with evidence of organ hypoper-
fusion and a systolic blood pressure <90 or >30 mmHg less
than the baseline or a requirement for the use of vasopressor
to maintain blood pressure.
Statistical analysis
The Student’s t-test was used to compare continuous vari-
ables, and 
2 or Fisher’s exact test to compare categorical vari-
ables. In identifying the independent risk factors, a backward
stepwise logistic regression analysis was used to control for
the effects of confounding variables. Variables with a p-value
<0.1 in the univariate analysis were candidates for multivari-
ate analysis. We used backward elimination of any variable
that did not contribute to the model on the grounds of the
likelihood ratio test, using a significance cutoff of 0.05. All
p-values were two-tailed, and p-values <0.05 were considered
statistically significant. The SPSS for Windows, version 11.5
software package (SPSS Inc, Chicago, IL, U.S.A.), was used
for all analyses.
RESULTS
Study population and clinical characteristics
Three hundred and seventy-seven consecutive patients with
K. pneumoniae bacteremia were included in this analysis. Am-
ong these, 191 cases were classified to be community-acquired
infection and the remaining 186 cases were classified to be
nosocomial infection. The demographic and clinical charac-
teristics of both groups are shown in Table 1. 
As for the underlying diseases, diabetes mellitus was more
common in community-acquired than in nosocomial infec-
tion (20.4% vs. 4.3%, p<0.001). Hematologic malignancy
was more frequently noted in patients with nosocomial com-
pared with community-acquired infection (28% vs. 4.7%,
p<0.001). Prior use of antibiotics, inappropriate antimicro-
bial therapy, central venous catheterization, indwelling uri-
nary catheter, and neutropenia were more frequent in noso-818 C.-I. Kang, S.-H. Kim, J.-W. Bang, et al.
comial infection (All p<0.05, Table 1). Also, the mean APA-
CHE II score was higher in nosocomial infection (11.75±
4.52 vs. 9.80±5.08, p<0.001). 
As for the primary site of infection, liver abscess were pre-
dominant in community-acquired infection. Among these
(n=21), 8 cases were identified to have disseminated infection
with metastatic infection, whereas no case in nosocomial infec-
tions was identified to have disseminated infection. Primary
site of infection was unknown in 76 (40.9%) cases of nosoco-
mial bacteremia, whereas in 49 (25.7%) cases of communi-
ty-acquired bacteremia (p=0.002) (Table 1).
Clinical outcomes and risk factors for mortality
The overall 30-day mortality rate of K. pneumoniae bacteremia
was 24.1% (91/377) and the mortality of nosocomial infec-
tions was significantly higher than that of community-acq-
uired infections (32.3% [60/186] vs. 16.2% [31/191], p<
0.001) (Table 2). Factors associated with 30-day mortality
are shown in Table 3. From the univariate analysis, the sig-
nificantly associated factors were; inappropriate empirical
antibiotics, inappropriate definitive antibiotics, ESC resis-
tance, ICU care, septic shock at initial presentation, neutrope-
nia, corticosteroid use, immunosuppressant use, nosocomial
acquisition, long hospital stay, pneumonia, and peritonitis
(all p<0.05) (Table 3). Pancreaticobiliary tract infection and
liver abscess were more common in survival group (Table 3).
Multivariate analysis using a logistic regression model, whi-
ch included the variables associated with mortality by univari-
ate analysis (p<0.1), showed that nosocomial acquisition was
one of the independent risk factors associated with 30-day
mortality (OR=2.32, 95% CI=1.11-4.86, p=0.025). Inappro-
priate definitive antibiotics, having peritonitis, having pneu-
monia, unknown site of infection, septic shock at initial pre-
sentation, and increased APACHE II score were also indepen-
dent risk factors of mortality in overall K. pneumoniae bactere-
mia cases (Table 4). When assessed the significant indepen-
dent factors associated with mortality in cases of communi-
ty-acquired infection, presentation with septic shock and in-
creased APACHE II score were also found to be independent
risk factors. Pancreaticobiliary tract infection was found to
be associated with survival (OR, 0.20; 95% CI, 0.05-0.82;
p=0.026). In cases of nosocomial infection, inappropriate de-
finitive antibiotics as well as presentation with septic shock
and increased APACHE II score were found to be indepen-
dent risk factors.
Clinical implication of antimicrobial resistance
Among 186 cases with nosocomial infection, 62 (33.3%)
cases were infected by ESC-resistant isolates, and 39 (21.0%)
cases were infected by CIP-resistant isolates. The ESC resis-
tance was detected in 35 (89.7%) of the 39 CIP-resistant K.
pneumoniae isolates. In comparison, only 27 (18.4%) of the
147 CIP-susceptible isolates were resistant to ESC (p<0.001).
No nosocomial isolate in this study was identified to be resis-
Community-
acquired 
(n=191)
Nosocomial
(n=186)
p
Age, mean yr±SD (range) 57±13 53±13 0.003
(17-86) (17-87)
Male 126 (66) 123 (66.1) 0.974
Underlying diseases
None 12 (6.3) 1 (0.5) 0.002
Diabetes mellitus 39 (20.4) 8 (4.3) <0.001
Benign pancreaticobiliary  24 (12.6) 7 (3.8) 0.002
tract disease
Hematologic malignancy 9 (4.7) 52 (28.0) <0.001
Solid tumor 45 (23.6) 52 (28.0) 0.329
Chronic liver disease 67 (35.1) 55 (29.6) 0.253
Primary site of infection
Pancreaticobiliary tract 50 (26.2) 39 (21.0) 0.234
Liver 21 (11.0) 4 (2.2) 0.001
Lung 10 (5.2) 11 (5.9) 0.774
Urinary tract 20 (10.5) 12 (6.5) 0.162
Peritoneum 39 (20.4) 43 (23.1) 0.524
Unknown 49 (25.7) 76 (40.9) 0.002
Prior antibiotics use 14 (7.3) 91 (48.9) <0.001
Inappropriate empirical antibiotics 4 (2.1) 29 (15.6) <0.001
Inappropriate definitive antibiotics 0 (0)   13 (7.0) <0.001
Central line catheterization 5 (2.6) 61 (32.8) <0.001
Indwelling urinary catheter 7 (3.7) 33 (17.7) <0.001
Neutropenia 18  (9.4) 52  (28.0) <0.001
CIP resistance 8 (4.2) 39 (21.0) <0.001
ESC resistance 7 (3.7) 62 (33.3) <0.001
Presentation with septic shock 42 (22.0) 50 (26.9) 0.269
APACHE II score, mean±SD 9.80±5.08 11.75±4.52 <0.001
(range) (0-28) (2-25)
Table 1. Demographic characteristics and underlying conditions
of patients with community-acquired vs. nosocomial K. pneumo-
niae bacteremia
Data represent patient numbers (%), otherwise indicated.
SD, standard deviation; CIP, ciprofloxacin; ESC, extended-spectrum
cephalosporins; APACHE, acute physiology and chronic health evalu-
ation.
Community-
acquired 
(n=191)
Nosocomial
(n=186)
p
Treatment failure rate at 72 hr
Clinical failure* 35 (18.3%) 69 (37.1%) <0.001
Microbiological failure
� 3 (1.6%) 14 (7.5%) 0.005
7-day mortality  18 (9.4%) 38 (20.4%) 0.003
30-day mortality  31 (16.2%) 60 (32.3%) <0.001
Table 2. Treatment outcome of patients with community-acquired
vs. nosocomial K. pneumoniae bacteremia
Data represent patient numbers (%).
*Absence of abatement or deterioration in any clinical parameters asso-
ciated with infection at 72 hr after initial antimicrobial therapy, 
� Isolation
of the organism in follow-up blood culture.Community vs. Nosocomial K. pneumoniae Bacteremia 819
tant to imipenem.
Among 191 cases with community-acquired infection, only
7 (3.7%) cases and 8 (4.2%) cases were infected by ESC-re-
sistant and CIP-resistant isolates, respectively. Of 8 commu-
nity-acquired isolates which were resistant to CIP, 3 isolates
were also resistant to ESC. All community-acquired isolates
in this study were susceptible to imipenem and amikacin. All
patients with community-acquired infection caused by ESC-
resistant K. pneumoniae had underlying illness and risk factors
for infection by resistant organisms, such as prior hospitaliza-
tion, prior use of antibiotics, or indwelling catheters. Of 7
cases infected by ESC-resistant isolates, 3 cases had the pre-
vious receipt of cephalosporin within 30 days
In nosocomial infection cases, we assessed the risk factors
for antimicrobial resistance. For ESC resistance, the signifi-
cantly associated factors were; ICU care, post-surgical state,
indwelling urinary catheter, invasive procedure within 72 hr
before onset of bacteremia, prior antibiotics use (cephalosporins,
aminoglycosides, and metronidazole) (all p<0.05). For CIP
resistance, the significantly associated factors were; post-sur-
gical state, indwelling urinary catheter, invasive procedure
within 72 hr before onset of bacteremia, prior use of antibi-
otics (cephalosporins, aminoglycosides, fluoroquinolones, and
Overall
Survivors 
(n=286)
p
Non-
survivors
(n=91)
Community-acquired (n=191)
Survivors 
(n=160)
p
Non-
survivors
(n=31)
Nosocomial (n=186)
Survivors 
(n=126)
p
Non-
survivors
(n=60)
Inappropriate empirical antibiotics 17 (5.9) 16 (17.6) 0.001 2 (1.3) 2 (6.5) 0.124 15 (11.9) 14 (23.3) 0.045
Inappropriate definitive antibiotics 3 (1.0) 10 (11.0) <0.001 N.C. 3 (2.4) 10 (16.7) <0.001
ESC resistance 46 (16.1) 23 (25.3) 0.048 5 (3.1) 2 (6.5) 0.318 41 (32.5) 21 (35.0) 0.739
CIP resistance 33 (11.5) 14 (15.4) 0.333 7 (4.4) 1 (3.2) 0.770 26 (20.6) 13 (21.7) 0.872
ICU care 5 (1.7) 9 (9.9) <0.001 N.C. 5 (4.0) 9 (15.0) 0.014
Septic shock at initial presentation 27 (9.4) 65 (71.4) <0.001 20 (12.5) 22 (71.0) <0.001 7 (5.6) 43 (71.7) <0.001
Neutropenia 46 (16.1) 24 (26.4) 0.028 12 (7.5) 6 (19.4) 0.084 34 (27.0) 18 (30.0) 0.668
Polymicrobial  30 (10.5) 10 (11.0) 0.893 17 (10.6) 3 (9.7) 0.875 13 (10.3) 7 (11.7) 0.781
Corticosteroid use 26 (9.1) 18 (19.8) 0.006 4 (2.5) 4 (12.9) 0.025 22 (17.5) 14 (23.3) 0.343
Immunosuppressant use 8 (2.8) 8 (8.8) 0.031 3 (1.9) 3 (9.7) 0.055 5 (4.0) 5 (8.3) 0.296
Nosocomial acquisition 126 (44.1) 60 (65.9) <0.001 --- ---
Long hospital stay (>14 days)* 65 (22.7) 37 (40.7) 0.001 N.C. 65 (51.6) 36 (60.0) 0.282
Underlying diseases
Hematologic malignancy 43 (15.0) 18 (19.8) 0.284 5 (3.1) 4 (12.9) 0.040 38 (30.2) 14 (23.3) 0.332
Solid tumor 70 (24.5) 27 (29.7) 0.323 35 (21.9) 10 (32.3) 0.212 35 (27.8) 17 (28.3) 0.937
Chronic liver disease 92 (32.2) 30 (33.0) 0.887 57 (35.6) 10 (32.3) 0.719 35 (27.8) 20 (33.3) 0.438
Pancreaticobiliary tract disease 30 (10.5) 1 (1.1) 0.005 24 (15.0) 0 (0) 0.016 6 (4.8) 1 (1.7) 0.432
Diabetes mellitus 37 (12.9) 10 (11.0) 0.624 32 (20.0) 7 (22.6) 0.744 5 (4.0) 3 (5.0) 0.714
Primary site of infection
Pneumonia 10 (3.5) 11 (12.1) 0.002 4 (2.5) 6 (19.4) 0.002 6 (4.8) 5 (8.3) 0.337
Pancreaticobiliary tract infection 77 (26.9) 12 (13.2) 0.007 47 (29.4) 3 (9.7) 0.022 30 (23.8) 9 (15.0) 0.168
Liver abscess 24 (8.4) 1 (1.1) 0.015 20 (12.5) 1 (3.2) 0.208 4 (3.2) 0 (0) 0.307
Peritonitis 54 (18.9) 28 (30.8) 0.017 32 (20.0) 7 (22.6) 0.744 22 (17.5) 21 (35.0) 0.008
Urinary tract infection  30 (10.5) 2 (2.2) 0.013 19 (11.9) 1 (3.2) 0.207 11 (8.7) 1 (1.7) 0.107
Unknown 88 (30.8) 37 (40.7) 0.081 36 (22.5) 13 (41.9) 0.023 52 (41.3) 24 (40.0) 0.869
Table 3. Risk factors associated with 30-day mortality in patients with K. pneumoniae bacteremia [Univariate analysis]
Data represent patient numbers (%), otherwise indicated.
N.C., No Cases identified; ESC, extended-spectrum cephalosporins; CIP, ciprofloxacin; ICU, intensive care unit.
*Hospital stay prior to onset of bacteremia.
Risk factors Adjusted OR (95% CI) p
In overall 
Peritonitis 3.66 (1.27-10.54) 0.016
Pneumonia 8.58 (2.22-33.20) 0.002
Unknown site of infection 5.05 (1.77-14.40) 0.002
Nosocomial acquisition 2.32 (1.11-4.86) 0.025
Inappropriate definitive antibiotics 19.29 (2.76-134.96) 0.003
Presentation with septic shock 27.11 (12.47-58.96) <0.001
Increased APACHE II score  1.15 (1.05-1.26) 0.002
(per 1-point increments)
In community-acquired infections
Presentation with septic shock 18.02 (6.34-51.24)  <0.001
Increased APACHE II score  1.11 (1.01-1.22) 0.031
(per 1-point increments)
Pancreaticobiliary tract infection 0.20 (0.05-0.82) 0.026
In nosocomial infections
Inappropriate definitive antibiotics 19.37 (2.61-143.75) 0.004
Presentation with septic shock 40.31 (13.17-123.42) <0.001
Increased APACHE II score  1.28 (1.12-1.46) <0.001
(per 1-point increments)
Table 4. Independent risk factors for mortality in patients with
K. pneumoniae bacteremia [Multivariate analysis]
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metronidazole) (all p<0.05). However, neutropenia was more
frequent in patients with ESC-susceptible K. pneumoniae bac-
teremia than in those infected with ESC-resistant isolates, and
also more frequent in those with CIP-susceptible K. pneumo-
niae bacteremia.
By multivariate logistic regression analysis, the significant
independent risk factors associated with ESC resistance were
invasive procedure before onset of bacteremia, prior use of me-
tronidazole, indwelling urinary catheter, and prior use of ce-
phalosporins. Also, the significant independent risk factors
for CIP resistance were invasive procedure before onset of bac-
teremia, prior use of fluoroquinolones, prior use of metronida-
zole, post-surgical state, and indwelling urinary catheter.
DISCUSSION
In the current study we present one of the largest recent
studies of both community and nosocomial bloodstream infec-
tions caused by K. pneumoniae. In this study of 377 episodes
of bloodstream infection, we found an overall 30-day mortali-
ty rate of 24%. Our study examines both community-acquired
and nosocomial bloodstream infections, allowing us to esti-
mate the proportion of bloodstream infection mortality that
is associated with nosocomial versus community-acquired
infections. 
We found that 66% of the crude mortality occurred among
patients with nosocomial bloodstream infection. In addition,
hospital acquisition (nosocomial status) of infection was st-
rongly associated with mortality in our multivariate analysis,
even after adjustments were made for underlying illness and
other confounding variables. 
Neoplastic diseases, such as hematologic malignancy and
solid tumor, were the most commonly associated condition
in patients with nosocomial K. pneumoniae bacteremia. Prior
antibiotics use, central line catheterization, indwelling urinary
catheter, and neutropenia were common in patients with neo-
plastic diseases. To the contrary, chronic liver disease (35%)
was the most commonly associated condition in patients with
community-acquired K. pneumoniae bacteremia. Diabetes mel-
litus was more commonly associated condition in patients
with community-acquired K. pneumoniae bacteremia than in
those with nosocomial bacteremia. The association of diabetes
mellitus and K. pneumoniae liver abscess was reported previ-
ously (11, 15-17). Bacteremic K. pneumoniae liver abscess occur-
red almost exclusively in patients with community-acuired
infection, consistent with a growing number of reports from
Asia describing this distinctive type of infection (10, 15-17).
In our study, 21 patients with liver abscess were identified
among 191 patients with community-acquired K. pneumoni-
ae bacteremia. Among these, 8 cases were identified to have
disseminated infection with metastatic infection. Metastatic
infection is a characteristic feature of K. pneumoniae liver abscess
(15-17). 
Pneumoniae carried a significantly poorer prognosis than
urinary tract infection, a finding that is in agreement with
the results of other studies (1, 5, 18). In our study, peritonitis
and unknown primary site of infection were also found to be
associated with higher mortality. Not surprisingly, increasing
severity of illness at the onset of bacteremia, septic shock, and
inappropriate definitive antimicrobial therapy were also asso-
ciated with increased mortality. These results suggest that
when K. pneumoniae bacteremia is suspected, the most signifi-
cant prognostic variables are the primary site of infection (i.e.,
pneumonia, peritonitis, or unknown) and the severity of the
underlying illness (i.e., higher APACHE II score or septic
shock). Also, as previously reported in our other study (19),
the adequacy of antimicrobial therapy was an important deter-
minant of survival. 
Nosocomial isolates were significantly more resistant to the
antimicrobial agents that were tested, except for imipenem,
when compared with the community-acquired isolates. More
than 30% of the nosocomial isolates were resistant to ESC,
which raises a concern over an increasing prevalence of ESBL-
producing K. pneumoniae, particularly in hospitals. We found
that the recent use of cephalosporins appeared to be a risk fac-
tor for ESC resistance in K. pneumoniae bacteremia (20). The
ESBL-producing K. pneumoniae infections are a risk factor asso-
ciated with treatment failure (21, 22). Therefore, aggressive
infection control and restrictions on the use of ESC should be
implemented.
We noted that an invasive procedure, an indwelling urinary
catheter, and post-surgical state were risk factors for infection
caused by antimicrobial-resistant strains (20). This finding
has important implications for nosocomial infection control,
as antibiotic-resistant strains in a hospital environment pose
a serious risk during the invasive procedures. As suggested by
Lautenbach et al., efforts should emphasize limiting contact
transmission of resistant isolates as well as controlling antibiotic
use (23). Neutropenic patients were significantly less likely
to have bacteremic with an ESC-resistant strain than with an
ESC-susceptible strain. As previously reported by Paterson et
al., this may be noteworthy because neutropenic patients are
usually subjected to enhanced infection control measures (5).
We limited our analysis of antibiotic use to 30 days prior
to bacteremia and were thus unable to access possible associ-
ations between antimicrobial resistance and more remote an-
tibiotic use. Another potential limitation was that molecular
epidemiologic analysis was not performed. However, there
were no evidences of clonal spread of the resistant organisms,
based on the epidemiological findings and the antimicrobial
susceptibility patterns of the isolates (data not shown). 
As this study was of the retrospective nature, the possibility
of the limitation in precluding accurate comparisons should
be borne in mind. The data were limited to the hospital re-
cord. Although the information concerning the in-hospital
antibiotic use was available from the medical record, the record
of the use of antibiotic at the outside hospital may not be accu-Community vs. Nosocomial K. pneumoniae Bacteremia 821
rate. Finally, our study was conducted in a large tertiary care
medical center, and thus many of our patients had serious un-
derlying illness, including neoplastic diseases and chronic liver
diseases. Also, it is noteworthy that 35% of our patients with
community-acquired bacteremia had chronic liver diseases,
reflecting the high prevalence of chronic hepatitis B virus in-
fection among the general population in Korea (24). Thus the
results regarding underlying illness of community vs. noso-
comial infections may not be applicable to other institutions.
In conclusions, neoplastic diseases were the most commonly
associated conditions in patients with nosocomial K. pneumo-
niae bacteremia, whereas diabetes mellitus and chronic liver
disease were the most commonly associated conditions in pa-
tients with community-acquired bacteremia. Bacteremic K.
pneumoniae liver abscess occurred almost exclusively in patients
with community-acquired infection. The mortality rate of
nosocomial infections was twice higher than that of commu-
nity-acquired infections. Of all community-acquired and no-
socomial isolates, 3.7% and 33.3%, respectively, were ESC-
resistant and 4.2% and 21%, respectively, were CIP-resistant.
In nosocomial infections, prior uses of ESC and CIP were found
to be independent risk factors for ESC and CIP resistance,
respectively. An invasive procedure, an indwelling urinary
catheter, and post-surgical state were also found to be risk
factors for infection. 
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